|
|
 | | | |
- close
- close
- close
- close
Vascular Solutions (VASC) |
Benzinga
May 16
Comment
Vascular Solutions (Nasdaq: VASC) announced today that it has filed a patent infringement complaint in the U.S. District Court for the District of Minnesota against Boston Scientific Corporation (NYSE: BSX). The complaint alleges that Boston...
StreetInsider.com
Apr 23
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Tops+Q1+EPS+by+1c/8272520.html for the full story.
MedPage Today
Mar 28
Comment
WASHINGTON (MedPage Today) -- The FDA has issued class I recalls on two hemostasis valves manufactured by Vascular Solutions because of a risk of air embolism.
Benzinga
Mar 27
Comment
In a report published Wednesday, Piper Jaffray analyst Thomas J. Gunderson initiated coverage on Vascular Solutions (NASDAQ: VASC) with an Overweight rating and $18.00 price target.
In the report, Gunderson noted, “We are initiating coverage...
Benzinga
Mar 18
Comment
In a report published Monday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $20.50 price target on Vascular Solutions (NASDAQ: VASC).
In the report, Mills noted, “Vascular Solutions announced that it initiated a...
Benzinga
Mar 18
Comment
In a report published Monday, Benchmark Company analyst James Terwilliger reiterated a Hold rating and $17.00 price target on Vascular Solutions (NASDAQ: VASC).
In the report, Terwilliger noted, “After the close of business on Friday, March...
StreetInsider.com
Mar 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Vascular+%28VASC%29+Unit+Recalls+Guardian+II%2C+II+NC+Valves%3B+FDA+Rates+as+Class+I/8189647.html for the full story.
Benzinga
Feb 6
Comment
Benchmark downgraded Vascular Solutions (NASDAQ: VASC) from Buy to Hold and announced a $17.00 price target.
Benchmark commented, "We are downgrading Vascular Solutions to a Hold rating from a Buy rating based on valuation as VASC is trading...
StreetInsider.com
Feb 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Vascular+Solutions%2C+Inc.+%28VASC%29+Tops+Q4+EPS+by+1c%3B+Guides+Q1%2C+FY13+Revs+and+EPS/8061574.html for the full story.
Benzinga
Oct 22
Comment
In a report published Monday, Feltl and Company reiterated its Buy rating on Vascular Solutions (NASDAQ: VASC), and raised its price target to $16.25.
Feltl and Company noted, “Vascular Solutions represents a unique type of company in the...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
